S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
OTCMKTS:BVRDF

Bureau Veritas (BVRDF) Stock Price, News & Analysis

$29.90
0.00 (0.00%)
(As of 04/18/2024 ET)
Today's Range
$29.90
$29.90
50-Day Range
$26.83
$29.90
52-Week Range
$23.07
$30.26
Volume
N/A
Average Volume
267 shs
Market Capitalization
$13.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BVRDF stock logo

About Bureau Veritas Stock (OTCMKTS:BVRDF)

Bureau Veritas SA provides laboratory testing, inspection, and certification services. It operates through six segments: Marine & Offshore; Agri-Food & Commodities; Industry; Buildings & Infrastructure; Certification; and Consumer Products. The company engages in inspecting, analyzing, auditing, and certifying the products, assets, and management systems of its customers in relation to regulatory or self-imposed standards, as well as issues compliance reports. It also provides laboratory and on-site testing services for manufacturing and process industries; inspection services for products, services, assets, and installations, as well as various services designed to control quality, verify quantity, and meet regulatory requirements; and certification services for management systems, products, and people. The company serves automotive and transportation, building and infrastructure, chemicals, commodities and agriculture, consumer products and retail, food, marine and offshore, oil and gas, and power and utilities industries, as well as financial services and public sectors. It operates in approximately 140 countries through a network of 1,600 offices and laboratories. Bureau Veritas SA was founded in 1828 and is headquartered in Neuilly-sur-Seine, France.

BVRDF Stock Price History

BVRDF Stock News Headlines

Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
L'état-major de Bureau Veritas
Bureau Veritas SA (BVI)
Bureau Veritas SA BVI
Bureau Veritas: Attractive On A Pullback
See More Headlines
Receive BVRDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bureau Veritas and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Private households
Sub-Industry
N/A
Current Symbol
OTCMKTS:BVRDF
Previous Symbol
NASDAQ:BVRDF
CIK
N/A
Employees
82,000
Year Founded
1828

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.35 billion
Cash Flow
$2.07 per share
Book Value
$4.77 per share

Miscellaneous

Free Float
N/A
Market Cap
$13.53 billion
Optionable
Not Optionable
Beta
1.07

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Ms. Hinda Gharbi M.Sc. (Age 53)
    Chief Executive Officer
  • Mr. Francois Chabas (Age 49)
    Executive VP of Finance & Group CFO
  • Mr. Philipp Karmires
    Executive VP and Chief Digital & Information Officer
  • Mr. Laurent Brunelle (Age 50)
    Head of Investor Relations
  • Ms. Beatrice Place Faget
    Executive Vice-President of Group Legal Affairs & Internal Audit
  • Mr. Juliano Cardoso
    Executive Vice-President of Corporate Development & Sustainability
  • Ms. Kathryn Dolan
    Executive Vice-President of Human Resources
  • Mr. Laurent Louail (Age 57)
    Executive Vice President of Commodities, Industry & Facilities - South & West Europe
  • Mr. Matthieu de Tugny
    Executive Vice President of Marine & Offshore Division
  • Ms. Catherine Chen
    Executive Vice President of Consumer Products Services division

BVRDF Stock Analysis - Frequently Asked Questions

Should I buy or sell Bureau Veritas stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bureau Veritas in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BVRDF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BVRDF, but not buy additional shares or sell existing shares.
View BVRDF analyst ratings
or view top-rated stocks.

How have BVRDF shares performed in 2024?

Bureau Veritas' stock was trading at $24.90 at the beginning of the year. Since then, BVRDF shares have increased by 20.1% and is now trading at $29.90.
View the best growth stocks for 2024 here
.

Are investors shorting Bureau Veritas?

Bureau Veritas saw a increase in short interest in March. As of March 15th, there was short interest totaling 683,400 shares, an increase of 10.3% from the February 29th total of 619,700 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.
View Bureau Veritas' Short Interest
.

How do I buy shares of Bureau Veritas?

Shares of BVRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BVRDF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners